Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.47 |
| ▸ | TACR2 | P21452 | 5/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7218603 | 0.81 | CNR2 (0.61) | CNR2TACR2CAPN1TRPV4CNR1 | |
| SCHEMBL7223448 | 0.80 | CNR2 (0.65) | CNR2TACR2CAPN1TRPV4CNR1 | |
| SCHEMBL7222272 | 0.76 | CNR2 (0.81) | CNR2CNR1 | |
| SCHEMBL7222255 | 0.67 | ALDH1A1 (0.59) | — | |
| SCHEMBL5960981 | 0.67 | ALDH1A1 (0.59) | — | |
| SCHEMBL7218551 | 0.66 | CNR2 (0.60) | CNR2TACR2TRPV4CNR1 | |
| SCHEMBL6600672 | 0.65 | ZAP70 (0.46) | — | |
| SCHEMBL7217580 | 0.65 | CNR2 (0.69) | CNR2TACR2TRPV4CNR1 | |
| SCHEMBL8300219 | 0.64 | ALOX15 (0.39) | — | |
| SCHEMBL12904976 | 0.64 | SIGMAR1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020119972-A1 | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-29 | — | — | US | claimed |
| US-6653304-B2 | Antiarthritic agents; skin disorders; anticarcinogenic agents | BRISTOL-MYERS SQUIBB CO. | 2003-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119972-A1 | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases | CNR1, CNR2, GPR18 | CNR2 2/4885TACR2 431/4885CAPN1 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.